Targeted Therapies Do Not Increase Cardiovascular Risk in Psoriasis
Researchers sought to investigate the effect of targeted therapies on cardiovascular risk in psoriasis and psoriatic arthritis.
Researchers sought to investigate the effect of targeted therapies on cardiovascular risk in psoriasis and psoriatic arthritis.
A 20-year-old woman presents to the dermatology clinic with a 5-day history of a mildly pruritic rash on both of her legs and feet. Can you diagnose this condition?
The EULAR issued recommendations for the screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases.
Using NHANES data, researchers estimated the prevalence of chronic axial pain, inflammatory back pain, axial spondyloarthritis, and peripheral arthritis in inflammatory bowel disease.
A team of researchers from Japan studied the presence of Sjögren syndrome among patients with anticentromere antibodies.
Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site.
The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
The approval was based on data from the phase 2/3 SELECT-AXIS 1 and the phase 3 SELECT-AXIS 2 trials.
A EULAR task force recently developed recommendations for the management of cardiovascular risk in patients with rheumatic and musculoskeletal diseases, including gout, lupus, and systemic sclerosis.